Diagnostic Performance of the Prostate Cancer Antigen 3 Test in Prostate Cancer: Systematic Review and Meta-analysis
- Authors
- Lee, Donghyun; Shim, Sung Ryul; Ahn, Sun Tae; Oh, Mi Mi; Moon, Du Geon; Park, Hong Seok; Cheon, Jun; Kim, Jong Wook
- Issue Date
- 10월-2020
- Publisher
- CIG MEDIA GROUP, LP
- Keywords
- Diagnosis; Meta-analysis; Prostate cancer antigen 3; Prostatic neoplasms; Prostate-specific antigen
- Citation
- CLINICAL GENITOURINARY CANCER, v.18, no.5, pp.402 - +
- Indexed
- SCIE
SCOPUS
- Journal Title
- CLINICAL GENITOURINARY CANCER
- Volume
- 18
- Number
- 5
- Start Page
- 402
- End Page
- +
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/52571
- DOI
- 10.1016/j.clgc.2020.03.005
- ISSN
- 1558-7673
- Abstract
- The purpose of this study was to assess the diagnostic accuracy of prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer through a systematic review and meta-analysis of 54 studies. Urinary PCA3 with a cutoff score of 35 had 71% pooled sensitivity and 68% pooled specificity. Urinary PCA3 is a noninvasive biomarker that can be used to aid in the diagnosis of prostate cancer. Purpose: To explore the diagnostic accuracy of prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer in this systematic review and meta-analysis. Patients and Methods: A systematic literature search of Medline, Embase, and Cochrane Library databases up to October 2019 was performed. The sensitivity, specificity, and diagnostic odds ratio with 95% confidence intervals (CIs) were calculated. The summary receiver operator characteristic graph came from individual studies. We also conducted metaregression analysis to identify the moderated factors. Results: Across 54 studies (17,575 patients), the pooled sensitivity, specificity, and diagnostic odds ratio of PCA3 were 0.71 (95% CI, 0.67-0.74), 0.68 (95% CI, 0.63-0.74), and 5.28 (95% CI, 4.28-6.51), respectively. The area under the summary receiver operator characteristic curve was 0.75 (95% CI, 0.71-0.79). Conclusion: Pooled data indicated that the PCA3 test had moderate sensitivity and specificity in the diagnosis of prostate cancer. PCA3 could be used as a noninvasive method for the diagnosis of prostate cancer. (C) 2020 The Author(s). Published by Elsevier Inc.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.